Observational Study of Rebismart®2.0 + MSdialog™ in Subjects With Remitting Multiple Sclerosis (ADHERQOL)

A Prospective, Observational, International, Multi-center Study to Measure the Relationship Between Relapse and Adherence in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients Treated With Rebismart®2.0 + MSdialog™, Assessing Quality of Life (ADHERQOL)

This is a 24-month, observational, prospective, multinational, multicenter study to determine the relationship between the relapse (percentage of relapse free subjects) and adherence in subjects diagnosed with RRMS treated with Rebif (interferon beta-1a) using the RebiSmart®2.0 and MSdialog™.

Inclusion Criteria:

• Diagnosed with RRMS according to McDonald criteria 2010
• Relapse free within 30 days before Baseline data collection
• Treatment with Rebif for 6 months or more prior to informed consent
• Already using RebiSmart®2.0 + MSdialog™ for patient reported outcome (PRO) assessments (at least once prior to informed consent)
• Females of childbearing potential must be willing to use appropriate contraception for the duration of the study
• EDSS score less than (<) 6
• Written informed consent obtained prior to any protocol-required data collection

Exclusion Criteria:

• Participation in other studies within 30 days before Baseline
• Female who is pregnant or breast feeding
• Significant psychiatric symptoms that, in the opinion of the Investigator, would impact subject ability to comply with treatment (as per standard clinical practice)
• Any contraindication for Interferon (IFN) beta-1a therapy as per Summary of Product Characteristics (SPC)
• Administration of any Multiple Sclerosis (MS) therapy, other than Rebif, within 6 months prior to informed consent